Overview
Febrile illness in Zambia most commonly refers to malaria, a mosquito‑borne infection caused by Plasmodium parasites. The disease is endemic across the country, especially in rural and peri‑urban areas where Anopheles mosquitoes thrive in stagnant water and during the rainy season (November‑April).
- Who it affects: Everyone can be infected, but children under five, pregnant women, HIV‑positive individuals, and travelers from non‑endemic regions are at highest risk of severe disease.
- Prevalence: According to the Zambia Ministry of Health, in 2023 there were ≈ 4.3 million confirmed malaria cases and ≈ 12 000 malaria‑related deaths, representing about 15 % of all outpatient visits during peak transmission months 1.
- Seasonality: Cases surge after the main rainy period (December–March) when mosquito breeding peaks.
Symptoms
Malaria’s clinical picture ranges from mild, flu‑like illness to life‑threatening severe disease. Symptoms typically appear 7‑30 days after an infective bite.
- Fever or chills – often cyclical, with “cold‑shaking” episodes.
- Headache – dull, throbbing, may be severe.
- Sweats – profuse after a febrile episode.
- Fatigue & weakness – can persist for weeks after parasites clear.
- Nausea, vomiting, or loss of appetite.
- Muscle and joint aches – “body‑ache” feeling.
- Abdominal pain or diarrhea.
- Enlarged spleen (splenomegaly) – may be palpable in chronic cases.
- Dark urine – especially with P. falciparum, indicating hemoglobinuria.
- Confusion or altered mental status – sign of cerebral malaria (severe).
- Rapid breathing, chest pain, or cough – may indicate pulmonary edema.
- Jaundice – from hemolysis.
Causes and Risk Factors
Primary cause
Malaria is transmitted when an infected female Anopheles mosquito bites a person, injecting sporozoites that travel to the liver, mature, and then infect red blood cells.
Key risk factors in Zambia
- Geography: Living in low‑lying plains, river valleys (e.g., Zambezi, Kafue) where mosquito breeding is prolific.
- Season: Rainy months increase vector density.
- Housing: Lack of screened windows, eaves gaps, or proper roofing.
- Socio‑economic status: Limited access to insecticide‑treated nets (ITNs) or prompt healthcare.
- Pregnancy: Placental sequestration of parasites increases maternal and fetal risk.
- Immunocompromise: HIV infection, malnutrition, or chronic disease.
- Travel history: Recent visit to high‑transmission zones or return from outside Zambia without prophylaxis.
Diagnosis
Early, accurate diagnosis is essential to prevent complications.
Point‑of‑care (POC) tests
- Rapid Diagnostic Test (RDT): Detects parasite antigens (HRP2 for P. falciparum, pLDH for other species). Results in 15–20 minutes; widely used in health posts.
- Microscopy (thin & thick blood smears): Gold standard when performed by trained technicians; quantifies parasite density.
Laboratory confirmation
- Complete blood count (CBC): May show anemia, thrombocytopenia.
- Liver function tests: Elevated bilirubin, transaminases in severe disease.
- Renal panel: Detects acute kidney injury.
- Blood glucose: Hypoglycemia is a common emergency in severe malaria.
When to suspect malaria despite a negative test
In high‑transmission settings, a negative RDT can be false‑negative (e.g., HRP2 gene deletions). Repeat testing after 12–24 hours or perform microscopy.
Treatment Options
Treatment follows national guidelines aligned with WHO recommendations.
Uncomplicated malaria
- Artemisinin‑based Combination Therapy (ACT): First‑line in Zambia.
- Artemether‑lumefantrine (Coartem) – 6‑dose regimen over 3 days.
- Artequick (artesunate‑amodiaquine) – 3‑day course.
- Alternative regimens for P. vivax or P. ovale (chloroquine‑sensitive areas): chloroquine 25 mg/kg over 3 days plus primaquine 0.25 mg/kg daily for 14 days to eradicate liver hypnozoites.
- Supportive care – antipyretics (paracetamol), adequate hydration, and rest.
Severe malaria
- Intravenous (IV) artesunate: 2.4 mg/kg at 0, 12, and 24 hours, then daily until oral feedable.
- If artesunate unavailable, IV quinine (10 mg/kg loading, then 10 mg/kg q8h) or artemether.
- Adjunctive measures:
- Correct hypoglycemia with dextrose.
- Manage anemia – blood transfusion if Hb < 5 g/dL.
- Treat seizures with diazepam or lorazepam.
- Renal support (dialysis) if acute kidney injury develops.
Lifestyle & non‑pharmacologic measures
- Sleep under insecticide‑treated bed nets (ITNs) every night.
- Wear long‑sleeved clothing and closed shoes, especially from dusk to dawn.
- Use indoor residual spraying (IRS) in homes where feasible.
Living with Zambia Febrile Illness (e.g., Malaria)
Daily management tips
- Adherence: Complete the full ACT course, even if you feel better after 2–3 days.
- Monitor temperature: Keep a log; seek care if fever persists >48 hours after treatment.
- Hydration: Drink oral rehydration solution (ORS) or plain water; avoid alcohol.
- Nutrition: Eat iron‑rich foods (leafy greens, beans) to combat anemia.
- Follow‑up: Return for a repeat malaria test 2–3 days after therapy to confirm clearance, especially in children.
- Pregnancy: Attend antenatal visits; receive intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine‑pyrimethamine (SP) as per national schedule.
- Co‑existing conditions: Inform clinicians about HIV status or other chronic illnesses; drug interactions may require dose adjustments.
Prevention
- Insecticide‑treated bed nets (ITNs): Distribute and replace every 3 years; ensure proper hanging.
- Indoor residual spraying (IRS): Conducted annually in high‑risk districts by the Ministry of Health.
- Environmental management: Eliminate stagnant water, clear vegetation around homes, and cover water storage containers.
- Personal repellents: DEET‑based lotions (10–30 %) applied to exposed skin.
- Travel prophylaxis: For visitors, take prescribed antimalarial prophylaxis (e.g., atovaquone‑proguanil) starting 1‑2 days before entry and continuing 7 days after departure.
- Vaccination: The RTS,S/AS01 (Mosquirix) vaccine is approved for children 6 weeks–17 months in pilot programs; consider where available.
Complications
If untreated or inadequately treated, malaria can progress to severe disease with a mortality rate up to 20 % in adults and 30 % in children.
- Cerebral malaria: Seizures, coma, long‑term neurological deficits.
- Severe anemia: May require transfusion; can lead to heart failure.
- Acute respiratory distress syndrome (ARDS).
- Acute renal failure.
- Hypoglycemia. Particularly in pregnant women and infants.
- Hemoglobinuria (“blackwater fever”).
- Miscarriage, preterm labor, low birth weight. In pregnant women.
When to Seek Emergency Care
Warning signs that require immediate medical attention:
- Altered consciousness, seizures, or inability to wake.
- Persistent vomiting or inability to keep fluids down.
- Rapid breathing, chest pain, or severe cough.
- Dark, tea‑colored urine or visible blood in stool/urine.
- Severe abdominal pain or swelling of the abdomen.
- Jaundice (yellowing of skin or eyes).
- Signs of severe anemia – extreme fatigue, dizziness, rapid heartbeat.
- Fever lasting more than 48 hours after completing antimalarial therapy.
- Pregnant woman with fever, especially in the first or third trimester.
Call emergency services (dial 991 in Zambia) or go to the nearest hospital emergency department immediately.
References
- 1. Zambia Ministry of Health. Malaria Annual Report 2023. Lusaka: MoH; 2024.
- 2. World Health Organization. World Malaria Report 2023. Geneva: WHO; 2023.
- 3. Mayo Clinic. “Malaria.” Accessed June 2026. https://www.mayoclinic.org
- 4. CDC. “Malaria – Diagnosis and Treatment.” Updated 2024. https://www.cdc.gov
- 5. NIH. “Severe Malaria.” National Institute of Allergy and Infectious Diseases. 2022.
- 6. Cleveland Clinic. “Malaria Prevention.” 2023. https://my.clevelandclinic.org